Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer’s disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity
Journal Title: Journal of Geriatric Care and Research - Year 2018, Vol 5, Issue 2
Abstract
Background: The donepezil-memantine combination is a US Food and Drug Administration (FDA)–approved medication to treat Alzheimer’s disease (AD). Galantamine is superior to donepezil because it is a positive allosteric modulator of the alpha-7 nicotinic acetylcholine receptor (α7nAChR). Although galantamine and memantine are both FDA approved for the treatment of AD, the combination is still underutilized in clinical practice. Aim: The objective of this review was to critically examine the mechanisms by which the galantamine-memantine combination may be superior to the donepezil-memantine combination in AD by targeting the cholinergic-nicotinic and glutamatergic systems concurrently. Method: PubMed and Google Scholar were searched using the keywords Alzheimer’s disease, cholinergic, glutamatergic, α7nAChR, N-methyl-D-aspartate (NMDA) receptors, donepezil, galantamine, memantine, clinical trials, and biomarkers. Results: AD is associated with several biomarkers such as kynurenine pathway (KP) metabolites, mismatch negativity (MMN), brain-derived neurotrophic factor (BDNF), and oxidative stress. In several preclinical studies, cognitive impairments significantly improved with the galantamine-memantine combination compared to either medication alone. Synergistic benefits were also seen with the combination. In a randomized controlled trial (RCT) in prodrome AD, cognition significantly improved with the galantamine-memantine combination compared to galantamine alone; cognition declined after galantamine was discontinued. However, in an RCT in AD, cognition did not significantly improve with the galantamine-memantine combination compared to galantamine alone. In a retrospective study in AD, the galantamine-memantine combination significantly improved cognition compared to the donepezil-memantine combination. Galantamine and memantine via the α7nACh and NMDA receptors can counteract the effects of kynurenic acid and enhance MMN and BDNF. Conclusion: Future studies with the galantamine-memantine combination with KP metabolites, MMN, and BDNF as biomarkers are warranted. Positive RCTs in AD may lead to FDA approval of the combination, resulting in greater utilization in clinical practice. In the meantime, clinicians may continue to use the galantamine-memantine combination to treat patients with AD.
Authors and Affiliations
Maju Mathew Koola, Agnieszka Nikiforuk, Anilkumar Pillai, Ajay K. Parsaik
Keywords
Related Articles
- EP ID EP552295
- DOI -
- Views 46
- Downloads 0
Cardio-metabolic syndrome – an intervention framework
Cardio-metabolic syndrome is a closely clustered group of dysfunctional metabolic parameters, predominantly characterised by a) impaired glucose tolerance or insulin resistance, b) central obesity or intra-abdominal adip...
Social impact of ageing in people with intellectual disabilities.
Introduction: People with intellectual disabilities have a longer life expectancy than ever before, which is resulting in an increase in population of the elderly in this group. There is scant information about ageing re...
Healthy Ageing Conference 2018: effectiveness of a public education event
This article summarises the role and effectiveness of Healthy Ageing Conference 2018 as a public education event; improving the general awareness about the issues relevant for elderly. It also tried to emphasize that the...
Clinical concerns of oral health in old age: an Indian perspective
Background: World Health Organization recognizes the oral health as an integral part of general health. Aims: This report attempts to highlight the clinical concerns of geriatric oral health in an Indian scenario. Method...
Proposal for the empowerment of interdependent self management support for people with dementia
The concept of ‘living well’ varies among individuals, and such diversity should be valued. However, maintaining co-beneficial relationships is critical for all the persons with dementia to live well with dementia, since...